CTLPP News and Press, Cantaloupe Inc 15% PRF PERPETUAL USD - Class A 0%

2024-05-21 06:53:48 ET Summary Abrams' 13F portfolio value decreased from $3.22B to $3.20B this quarter. The number of holdings in the portfolio decreased from 14 to 12. The top three stakes in the portfolio make up approximately 48% of the total, while the top five holdings m...

2024-05-10 02:33:08 ET Cantaloupe, Inc. (CTLP) Q3 2024 Earnings Conference Call May 9, 2024 17:00 ET Company Participants Dara Dierks - Investor Relations Ravi Venkatesan - Chief Executive Officer Scott Stewart - Chief Financial Officer Conference Call Part...

2024-02-09 22:17:09 ET Summary David Abrams' 13F portfolio value increased from $3.03B to $3.22B this quarter. Meta Platforms and Teva Pharmaceutical saw stake decreases in Abrams' portfolio. Abrams kept steady positions in Lithia Motors, Asbury Automotive, Alphabet Inc., and ...

2024-02-08 23:02:03 ET Cantaloupe, Inc. (CTLP) Q2 2024 Earnings Conference Call February 8, 2024 17:00 ET Company Participants Dara Dierks - Investor Relations Ravi Venkatesan - Chief Executive Officer Scott Stewart - Chief Financial Officer Conference Call...

2023-11-09 20:34:08 ET Cantaloupe, Inc. (CTLP) Q1 2024 Results Conference Call November 09, 2023 5:00 PM ET Company Participants Dara Dierks - IR Ravi Venkatesan - CEO Scott Stewart - CFO Conference Call Participants Josh Nichols - B. Riley Gary P...

2023-09-06 19:57:10 ET Cantaloupe, Inc. (CTLP) Q4 2023 Earnings Conference Call August 06, 2023, 05:00 PM ET Company Participants Marissa Neuman - Investor Relations Ravi Venkatesan - Chief Executive Officer Scott Stewart - Chief Financial Officer Conferenc...

2023-08-24 02:48:55 ET Summary Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. The number of holdings in the portfolio increased from 15 to 16. The top three stakes in the portfolio make up approximately 45% of the total. This article is par...

2023-05-25 01:43:01 ET Summary David Abrams’ 13F portfolio value increased this quarter from $2.80B to $3.16B. The number of positions remained steady at 15. Cantaloupe stake was increased while decreasing Teva Pharmaceutical. The top three positions are Lithia Motors, ...

2023-05-06 11:55:03 ET Cantaloupe, Inc. (CTLP) Q3 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Dara Dierks – Investor Relations Ravi Venkatesan – Chief Executive Officer Scott Stewart – Chief Financial Officer ...

2023-04-02 11:25:11 ET Summary CTLP is currently loss-making in the bottom line and it does not appear likely to become profitable in the foreseeable future. The company relies on non-financing means of generating cash which is not sustainable. The company may look cheap compa...